Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey
- 24 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Immunology
- Vol. 232, 108860
- https://doi.org/10.1016/j.clim.2021.108860
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesAnnals of Internal Medicine, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsThe New England Journal of Medicine, 2021
- BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in IsraelClinical Microbiology & Infection, 2021
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational studyThe Lancet Infectious Diseases, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020